|
|
Sosunov V., Mischenko V., Eruslanov B., Svetoch E., Shakina Y., Stern N., Majorov K.,
Sorokoumova G., Selishcheva A., Apt A. |
Antimycobacterial activity of bacteriocins and their complexes with liposomes. |
J Antimicrob Chemother. 2007 Mar 8; [Epub ahead of print] |
| |
|
Abstract
Objectives Bacteriocins (Bcn) are natural peptides that are secreted by several taxonomically
distant bacteria and exert bactericidal activity against other bacterial species. Their capacity
to inhibit growth of virulent Mycobacterium tuberculosis H37Rv was evaluated in this study.
Methods Five different Bcn were isolated and purified from bacterial culture supernatants,
their amino acid sequence was determined, and activity against mycobacteria assessed in three
different models: in vitro mycobacterial cultures, in vitro infection of mouse macrophages
and in vivo high-dose infection of inbred mice. Results In the in vitro model, four out of
five Bcn exhibited stronger antimycobacterial activity than equal concentrations of a widely
used anti-TB antibiotic, rifampicin. These Bcn were non-toxic for mouse macrophages at a
concentration of 0.1 mg/L (>MIC(90) of these compounds). Pure Bcn did not inhibit mycobacterial
growth within murine macrophages when added at 0.01-0.1 mg/L, suggesting that at physiologically
tolerable concentrations these molecules do not penetrate through the membrane of eukaryotic cells.
However, when administered as a complex with phosphatidylcholine-cardiolipin liposomes, Bcn5 (selected
as a model compound due to its cytotoxicity and antimycobacterial activity regular titration curves)
demonstrated capacity both to inhibit intracellular growth of M. tuberculosis and to prolong survival
of mice in an acute TB model. Conclusions Given that the mechanism of Bcn bactericidal activity differs
from that of all commonly used antibiotics, their possible involvement in complex TB therapies deserves
further study. |
Вернуться в раздел
Публикации
|
|